VTRS
$VTRS
Viatris Inc.
Global pharmaceutical company formed from Mylan and Pfizer Upjohn merger making generic and branded drugs.
HealthcareSubscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
VTRS: Value Play with Strong FCF Catalysts
Viatris ($VTRS) trades near $13 with a sub-1 P/B, a 3.7% yield, and a low forward P/E, while analysts lift targets after debt reduction and pipeline updates. The stock offers yield plus potential upside if FCF converts to sustainable earnings.
Mar 30, 2026